Purpose: To evaluate outcomes of glaucoma drainage device (GDD) implantation children with uveitic glaucoma.
Design: Retrospective interventional case series.
Methods: Success was defined as intraocular pressure (IOP) ≥5 and ≤21 mm Hg. Failure was defined at final follow-up when the IOP was outside the success criterion, and visual function was no perception of light or if further glaucoma surgery (excluding removal of intraluminal stent suture or needling) was required.
Results: Fifty eyes of 36 children with uveitic glaucoma underwent GDD implantation. Mean age at surgery was 10.1±3.1 years (range 5-17) with a mean follow-up of 113±61 months (range 8-228). Mean cumulative probabilities of success (95% CI) were 0.98 (0.86-1.00) at 1 year, 0.87 (0.73-0.94) at 5 years, and 0.59 (0.32-0.78) at 15 years. Fourteen tubes were classified as failed, with 12 due to uncontrolled IOP (11 eyes required a second GDD); 1 eye, removal of the tube due to plate exposure; and 1 eye, lost light perception. Postoperative complications occurred in 36% of patients and included hypotony (22%), tube exposure (6%), tube obstruction (4%), corneal decompensation (2%), and cystoid macular edema (2%). Visual acuity remained stable (preoperation 0.35±0.42 vs postoperation 0.45±0.67, P = .49). IOP was significantly reduced from 31.4±7.5 mm Hg to 14.4±5.1 mm Hg (P < .0001) as were the number of glaucoma medications 3.5±1.0 vs 1.1±1.3 (P < .0001).
Conclusions: Refractory pediatric uveitic glaucoma can be treated successfully by GDD implantation. Further interventions to manage consequences of glaucoma or the underlying disease are common, and visual function is maintained in the majority of cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajo.2023.02.004 | DOI Listing |
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology, Hadassah Medical Center, Jerusalem, Israel.
Difluprednate (DFP) (difluoroprednisolone butyrate acetate, or DFBA) ophthalmic emulsion 0.05% (Durezol®) was the first potent corticosteroid to be approved for both postoperative pain and inflammation in 2008. In June 2012, it was approved for the treatment of endogenous anterior uveitis.
View Article and Find Full Text PDFOcul Immunol Inflamm
December 2024
Department of Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Purpose: To present the outcomes of Ahmed glaucoma valve (AGV) implantation in uveitic glaucoma (UG) in a tertiary eye center in Riyadh, Saudi Arabia.
Methods: A retrospective review of all UG patients who underwent AGV implantation at a single, tertiary care eye center from January 2008 to December 2018. The main outcome measures were change in mean intraocular pressure (IOP), number of antiglaucoma medications, overall success rate in different follow-up periods, complete and qualified success from last follow up, and complications.
Am J Ophthalmol
November 2024
Department of Ophthalmology and Schepens Eye Research Institute (C.S.F., J.H.K.), Massachusetts Eye and Ear Infirmary; and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Sight for Souls (J.H.K.), Bellevue, Washington, USA; MCM Eye Unit (J.H.K.), MyungSung Christian Medical Center (MCM) General Hospital and Myung Sung Medical School, Addis Ababa, Ethiopia; Department of Ophthalmology (J.H.K.), Addis Ababa University School of Medicine, Addis Ababa, Ethiopia. Electronic address:
Purpose: To evaluate the incidence, remission, and relapse of post-surgical cystoid macular edema (PCME) following cataract surgery in inflammatory eye disease.
Methods: A total of 1859 eyes that had no visually significant macular edema prior to cataract surgery while under tertiary uveitis management were included. Standardized retrospective chart review was used to gather clinical data.
Can J Ophthalmol
May 2024
Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN. Electronic address:
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel.
Purpose: To assess the risk of gonioscopy-assisted transluminal trabeculotomy (GATT) inducing an uveitic flare-up in patients with uveitic glaucoma (UG).
Methods: This retrospective study included consecutive UG patients who underwent GATT at a single medical center between June 2020 and September 2022. The main outcome measure was the occurrence of a surgery-related uveitic complication defined as either an uveitic flare-up defined by the Standardization of Uveitis Nomenclature (SUN) criteria, or the appearance of cystoid macular edema (CME) from 2 weeks to 3 months after surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!